L3VLUP
ProSign in

IDXX · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IDXXJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IDXX
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterIDXXJNJ
Q3 202018 holders, $2.9bn30 holders, $26.2bn
Q4 202015 holders, $3.5bn32 holders, $26.6bn
Q1 202122 holders, $3.5bn31 holders, $25.3bn
Q2 202118 holders, $4.5bn37 holders, $25.6bn
Q3 202120 holders, $4.6bn40 holders, $24.1bn
Q4 202117 holders, $4.9bn33 holders, $25.2bn
Q1 202218 holders, $4.7bn35 holders, $28.2bn
Q2 202220 holders, $3.5bn33 holders, $26.9bn
Q3 202217 holders, $2.7bn36 holders, $25.4bn
Q4 202213 holders, $3.5bn35 holders, $27.6bn
Q1 202318 holders, $4.2bn42 holders, $24.5bn
Q2 202316 holders, $3.7bn38 holders, $25.0bn
Q3 202315 holders, $3.2bn37 holders, $18.9bn
Q4 202316 holders, $4.1bn31 holders, $19.0bn
Q1 202417 holders, $3.7bn32 holders, $19.7bn
Q2 202413 holders, $3.7bn35 holders, $20.4bn
Q3 202417 holders, $3.8bn28 holders, $22.3bn
Q4 202422 holders, $2.6bn37 holders, $20.4bn
Q1 202517 holders, $2.4bn32 holders, $20.5bn
Q2 202511 holders, $2.5bn31 holders, $18.4bn
Q3 202510 holders, $2.8bn32 holders, $23.7bn
Q4 202514 holders, $5.1bn29 holders, $27.8bn
Q1 202616 holders, $4.7bn34 holders, $35.6bn
Q2 202622 holders, $4.9bn33 holders, $39.1bn
IDXX

Idexx Labs Inc

Holders
16
Reported value
$4.7bn
Buyers
23
Sellers
13

Breadth +10 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUP
JNJ

Johnson & Johnson

Holders
34
Reported value
$35.6bn
Buyers
21
Sellers
18

Breadth +3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 39 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only IDXX (5)

Harris Associates LP, Holocene Advisors LP, Point72 Asset Management LP, Polen Capital Management LLC, Schonfeld Strategic Advisors LLC

Only JNJ (23)

AllianceBernstein LP, AQR Capital Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Rokos Capital Management LLP, Soros Fund Management LLC, Verition Fund Management LLC, Walleye Capital LLC, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →